Diadexus, Inc.
Records under this name other than patents Diadexus, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,964,195 | Ovr 110 Antibody Compositions and Methods of Use Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 8,349,574 | Methods of determining patient response by measurement of Her-3 Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,766,242 | Methods of determining patient response by measurement of HER-3 and P95 Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,775,382 | Methods of determining patient response by measurement of HER-3 Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 11,401,344 | Methods for Determining the Likelihood of Survival and for Predicting Likelihood of Metastasis in Cancer Patients Formerly held In force · Low confidence | In force | Low confidence | |
| US 9,110,066 | HER-3 antibodies and methods of use Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,460,880 | Compositions, splice variants and methods relating to ovarian specific genes and proteins Formerly held Term ended Term ended Jun 16, 2025 · High confidence | Term ended | Term ended Jun 16, 2025 | High confidence |
| US 8,444,971 | OVR110 antibody compositions and methods of use Formerly held Lapsed on the fee record Ended May 21, 2025 · From the USPTO record | Lapsed on the fee record | Ended May 21, 2025 | From the USPTO record |
| US 7,619,068 | Ovr110 antibody compositions and methods of use Formerly held Term ended Term ended May 10, 2024 · From the USPTO record | Term ended | Term ended May 10, 2024 | From the USPTO record |
| US 8,906,369 | Ovr110 antibody compositions and methods of use Formerly held Lapsed on the fee record Ended Dec 9, 2022 · From the USPTO record | Lapsed on the fee record | Ended Dec 9, 2022 | From the USPTO record |